The ampakine CX546 restores the prepulse inhibition and latent inhibition deficits in mGluR5-deficient mice

Neuropsychopharmacology

Volumn 32, Issue 4, 2007, Pages 745-756

  Lipina, Tatiana ^a   Weiss, Karin ^a   Roder, John ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Aniracetam; CX546; Latent inhibition; mGluR5 knockout mice; MK 801; PPI

Indexed keywords

AMPA RECEPTOR; AMPA RECEPTOR AGONIST; AMPAKINE; ANIRACETAM; CX 546; DIZOCILPINE; METABOTROPIC RECEPTOR 5; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONDITIONING; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; GENE MUTATION; GENETIC ENGINEERING; KNOCKOUT MOUSE; LATENT INHIBITION; MENTAL DISEASE; MOUSE; MOUSE STRAIN; NEUROMODULATION; NEWBORN; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

ACOUSTIC STIMULATION; ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; CONDITIONING, CLASSICAL; DIOXOLES; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG INTERACTIONS; ELECTROSHOCK; EXCITATORY AMINO ACID ANTAGONISTS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURAL INHIBITION; PIPERIDINES; PYRROLIDINONES; RECEPTORS, METABOTROPIC GLUTAMATE; STARTLE REACTION;

EID: 33947230697     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301191     Document Type: Article

References (77)

1. Ango F, Prezeu L, Muller T, Tu JC, Xiao B, Worley PF et al (2001). Agonist-independent activation of metabotropic glutamate receptors by the intracellular protein Homer. Nature 411: 962-965.
2. Awad H, Hubert GW, Smith Y, Levey AI, Conn PJ (2000). Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 20: 7871-7879.
3. Ballard TM, Puly-Evers M, Higgins GA, Ouagazzal AM, Mutel V, Borroni E et al (2002). Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity. J Neurosci 22: 6713-6723.
4. Bardgett ME, Boeckman R, Krochmal D, Fernando H, Ahrens R, Csernansky JG (2003). NMDA receptor blockade and hippocampal neuronal loss impair fear conditioning and position habit reversal in C57BL/6J mice. Brain Res Bull 60: 131-142.
5. Bills C, Schachtman TR, Serfozo P, Spooren WP, Gasparini F, Simonvi A (2005). Effects of metabotropic glutamate receptor 5 on latent inhibition in conditioned taste aversion. Behav Brain Res 157: 71-78.
6. Black MD (2005). Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. Psychopharmacology (Berlin) 179: 154-163.
7. Braff D, Geyer MA, Swerdlow NR (2001). Sensorimotor gating and schizophrenia: human and animal model studies. Arch Gen Psychiatry 47: 181-188.
8. Brody SA, Conquet F, Geyer MA (2004b). Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice. Psychopharmacology 172: 187-195.
9. Brody SA, Dulawa SC, Geyer MA, Conquet F (2004a). Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors. Mol Psychiatry 9: 35-41.
10. Bruno V, Ksiazek I, Battaglia G, Lukic S, Leonhardt T, Sauer D et al (2000). Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective. Neuropharmacology 39: 2223-2230.
11. Castellanos FX, Fine EJ, Kaysen D, Marsh WL, Rapport JL, Hallet M (1996). Sensorimotor gaiting in boys with Tourette's syndrome and ADHD: preliminary results. Biol Psychiatry 39: 33-41.
12. Chapman AG, Nanan K, Williams M, Meldrum BS (2000). Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styrylpyridine (SIB 1893). Neuropharmacology 39: 1567-1574.
13. Cohen E, Sereni N, Kaplan O, Weizman A, Kikinzon L, Weiner I et al (2004). The relation between latent inhibition and symptom - types in young schizophrenics. Behav Brain Res 149: 113-122.
14. Conn PJ, Pin JP (1997). Pharmacology and functions of metabotropic glutamate receptors. Ann Rev pharmacol Toxicol 37: 261-281.
15. Depoortere R, Perrault G, Sanger DJ (1997). Some, but not all, antipsychotic drugs potentiate a low level of prepulse inhibition shown by rats of the Wistar strain. Behav Pharmacol 8: 364-372.
16. Devon RS, Anderson S, Teaguo PW, Muir WJ, Murray V, Pelosi AJ et al (2001). The genomic organisation of the metabotropic glutamate receptor subtype 5 gene, and its association with schizophrenia. Mol Psychiatry 6: 311-314.
17. Doherty AJ, Palmer MJ, Henley JM, Collingridge GL, Jane DE (1997). RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGluR5, but no mGluR1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. Neuropharmacology 36: 265-267.
18. Gainetdinov RR, Mohn AR, Bohn LM, Caron MG (2001). Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. Proc Natl Acad Sci USA 98: 11047-11054.
19. Gaisler-Salomon I, Weiner I (2003). Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol. Psychopharmacology (Berlin) 166: 333-342.
20. Geyer MA, Ellenbroek B (2003). Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27: 1071-1079.
21. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001). Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berlin) 156: 117-154.
22. Goff DC, Coyle JT (2001). The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158: 1367-1377.
23. Goff DC, Leahy L, Berman I, Posever T, Herz L, Leon AC et al (2001). A placebo-controlled pilot study of the AMPAkine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 21: 484-487.
24. Gogos JA, Santha M, Takacs Z, Beck KD, Luine V, Lucas LR et al (1999). The gene encoding proline dehydrogenase modulates sensorimotor gating in mice. Nat Genet 21: 434-439.
25. Goldman-Rakic PS (1994). Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci 6: 348-357.
26. Granger R, Staubli U, Davis M, Perez Y, Nilsson L, Rogers GA et al (1993). A drug that facilitates glutamatergic transmission reduces exploratory activity and improves performance in a learning-dependent task. Synapse 15: 326-329.
27. Gray NS, Hemsley DR, Gray JA (1992). Abolition of latent inhibition in acute, but not chronic, schizophrenics. Neurol Psychiatr Brain Res 1: 83-89.
28. Hanley JG, Henley JM (2005). PICK1 is a calcium-sensor for NMDA-induced AMPA receptor trafficking. EMBO J 24: 3266-3278.
29. Hannan AJ, Blakemore C, Katsnelson A, Vitalis T, Huber KM, Bear M et al (2001). PLC-β1, activated via mGluRs, mediates activity-dependent differentiation in cerebral cortex. Nat Neurosci 4: 282-288.
30. Henry SA, Dulawa SC, Conquet E, Geyer MA (1999). Sever disruption of prepulse inhibition (PPI) in mice lacking mGluR5. Soc Neurosci Abstr 25: 405-412.
31. Heuss C, Scanziani M, Gahwiler BH, Gerber U (1999). G-protein-independent signalling mediated by metabotropic glutamate receptors. Nat Neurosci 2: 1070-1077.
32. Homayoun H, Stefani MR, Adams BW, Tamagan GD, Moghaddam B (2004). Functional interaction between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors, and dopamine release. Neuropsychopharmacology 29: 1259-1269.
33. Huang Y, Lu W, Ali DW, Pelkey KA, Pitcher GM, Lu YM et al (2001). CAKbeta/Pyk2 kinase is a signaling link for induction of long-term potentiation in CA1 hippocampus. Neuron 29: 485-496.
34. Huang EP, Stevens CF (1998). The matter of mind: molecular control of memory. Essays Biochem 33: 165-178.
35. Husi H, Ward MA, Choudhary JS, Blackstock WP, Grant SG (2000). Proteomic analysis of NMDA receptor-adhesion protein signaling complexes. Nat Neurosci 3: 661-669.
36. Isaac JTR, Nicoll RA, Malenka RC (1995). Evidence for silent synapses: implications for the expression of LTP. Neuron 15: 427-434.
37. Iwasato T, Erzurumlu RS, Huerta PT, Chen DF, Sasaoka T, Ulupinar E et al (1997). NMDA receptor-dependent refinement of somatotopic maps. Neuron 19: 1201-1210.
38. Javitt DC, Balla A, Sershen H, Lajtha A (1999). Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Biol Psychiatry 45: 668-679.
39. Javitt DC, Zukin SR (1991). Mechanisms of phencyclidine (PCP)-N-methyl-D-asparate (NMDA) receptor interaction: implications for schizophrenia. In: Tamminga CA, Schulz SC (eds). Neuropsychological Study of Schizophrenia in Schizophrenia Research: Advances in Neuropsychiatry and Psychopharmacology. Raven Press: New York. pp 13-20.
40. Jia Z, Lu Y, Henderson J, Taverna F, Romano C, Abramow-Newerly W et al (1998). Selective abolition of the NMDA component of long-term potentiation in mice lacking mGluR5. Learn Mem 5: 331-343.
41. Johnson SA, Luu NT, Herbst TA, Knapp R, Lutz D, Arai A et al (1999). Synergistic interactions between AMPAkines and antipsychotic drugs. J Pharmacol Exp Ther 289: 392-397.
42. Kew JNC, Kemp JA (2005). Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology 179: 4-29.
43. Kim JJ, Jung MW (2006). Neural circuits and mechanisms involved in Pavlovian fear conditioning: a critical review. Neurosci Biobehav Rev 30: 188-202.
44. Kinney GG, Burno M, Campbell UC, Hernandez LM, Rodriguez D, Bristol LJ et al (2003). Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J Pharmacol Exp Ther 306: 116-123.
45. Kozela E, Pilc A, Popik P (2003). Inhibitory effects of MPEP, an mGluR5 antagonist, and memantine, an N-methyl-D-asparate receptor antagonist, on morphine antinociceptive tolerance in mice. Psychopharmacology 165: 245-251.
46. Larson J, Qach CN, LeDuc BQ, Nguyen A, Rogers GA, Lynch G (1996). Effects of an AMPA receptor modulator on methamphetamine-induced hyperactivity in rats. Brain Res 738: 353-356.
47. LeDoux JE (2000). Emotion circuits in the brain. Annu Rev Neurosci 23: 155-184.
48. Lipina T, Labrie V, Weiner I, Roder J (2005). Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology 179: 54-67.
49. Lu YM, Jia Z, Janus C, Henderson JT, Gerlai R, Wojtowicz JM et al (1997). Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J Neurosci 17: 5196-5205.
50. Lynch G (2004). AMPA receptor modulators as cognitive enhancers. Curr Opin Pharmacol 4: 4-11.
51. Maren S, Tocco G, Standley S, Baudry M, Thompson RF (1993). Postsynaptic factors in the expression of long-term potentiation (LTP): increased glutamate receptor binding following LTP induction in vivo. Proc Natl Acad Sci USA 90: 9654-9658.
52. Morris RG, Davis S, Butcher SP (1990). Hippocampal synaptic plasticity and NMDA receptors: a role in information storage? Philos Trans R Soc Lond B Biol Sci 329: 187-204.
53. Moser PC, Hitchcock JM, Lister S, Moran PM (2000). The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Res Rev 33: 275-307.
54. Nagarajan N, Quast C, Boxall AR, Shahid M, Rosenmund C (2001). Mechanisms and impact of allosteric AMPA receptor modulation by the AMPAkine CX546. Neuropharmacology 31: 650-663.
55. Ohnuma T, Augood SJ, Arai H, McKenna PJ, Ernson PC (1998). Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Mol Brain Res 56: 207-217.
56. Olney JW, Newcomer JW, Farber NB (1999). NMDA receptor hypofunction model of schizophrenia. J Psychiatry Res 33: 523-533.
57. Olivier B, Leahy C, Mullen T, Paylor R, Groppi VE, Sarnyai Z et al (2001). The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics? Psychopharmacology (Berlin) 156: 284-290.
58. Partin KM, Fleck MF, Mayer ML (1996). AMPA receptor flip/flop mutants affecting deactivation, desensitization and modulation by cyclothiazide, aniracetam and thiocyanate. J Neurosci 16: 6634-6647.
59. Paul IA, Skolnick P (2003). Glutamate and depression clinical and preclinical studies. Ann NY Acad Sci 1003: 250-272.
60. Salter MW, Kalia LV (2004). Src kinases: a hub for NMDA receptor regulation. Nat Rev Neurosci 5: 317-328.
61. Shadach E, Gaisler I, Schiller D, Weiner I. (2000). The latent inhibition model dissociates between clozapine, haloperidol, and ritanserin. Neuropsychopharmacology 23: 151-161.
62. Smith AM, Wehner JM (2002). Aniracetam improves contextual fear conditioning and increases hippocampal γ-PKC activation in DBA/2J mice. Hippocampus 12: 76-85.
63. Spooren WP, Vassout A, Nejt HC, Kuhn R, Gasparini F, Roux S et al (2000). Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther 295: 1267-1275.
64. Staubli U, Rogers G, Lynch G (1994). Facilitation of glutamate receptors enhances memory. Proc Natl Acad Sci USA 91: 777-781.
65. Swerdlow NR, Braff DL, Taaid N, Geyer MA (1994). Assessing the validity of an animal model of deficient sensorimotor gaiting in schizophrenia patients. Arch Gen Psychiatry 51: 139-154.
66. Swerdlow NR, Geyer MA (1993). Clozapine and haloperidol in an animal-model of sensoriomotor gaiting deficits in schizophrenia. Pharmacol Biochem Behav 44: 741-744.
67. Swerdlow NR, Paulsen J, Braff DL, Butters N, Geyer MA, Swerdlow MR (1995). Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease. J Neurol Neurosurg Psychiatry 58: 192-200.
68. Szumlinski KK, Lominac KD, Kleschen MJ, Oleson EB, Dehoff MH, Schwarz MK et al (2005). Behavioral and neurochemical phenotyping of Homer1 mutant mice: possible relevance to schizophrenia. Genes Brain Behav 4: 273-278.
69. Tsuzuki K, Takeuchi T, Ozawa S (1992). Agonist- and subunit-dependent potentiation of glutamate receptors by a nootropic drug aniracetam. Mol Brain Res 16: 105-110.
70. Tu JC, Xiao B, Naisbitt S, Yuan JP, Petralia RS, Brakemn P et al (1999). Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 23: 583-592.
71. Ugolini A, Corsi M, Bordi F (1999). Potentiation of NMDA and AMPA responses by the specific mGluR5 agonist CHPG in spinal cord motoneurons. Neuropharm 38: 1569-1576.
72. Vanover KE (1997). Effects of AMPA receptor positive modulators on amphetamine- and dizocilpine-induced locomotion. Eur J Pharmacol 332: 115-119.
73. Wan FJ, Geyer MA, Swerdlow NR (1995). Presynaptic dopamineglutamate interactions in the nucleus accumbens regulate sensorimotor gating. Psychopharmacology (Berlin) 120: 433-441.
74. Weiner I (2003). The 'two-headed' latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology (Berlin) 169: 257-297.
75. Weiner I, Lubow RE, Feldon J (1984). Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats. Psychopharmacology (Berlin) 83: 194-199.
76. Weiner I, Schiller D, Gaisler-Salomon I (2003). Disruption and potentiation of latent inhibition by risperidone: the latent inhibition model of atypical antipsychotic action. Neuropsychopharmacology 28: 499-509.
77. Weiner I, Shadach E, Barkai R, Feldon J (1997). Haloperidol- and clozapine-induced enhancement of latent inhibition with extended conditioning: implications for the mechanisms of action of neuroleptic drugs. Neuropsychopharmacology 16: 42-50.